Literature DB >> 29104858

IDH mutational status and the immune system in gliomas: a tale of two tumors?

Bryan D Choi1, William T Curry1.   

Abstract

Entities:  

Keywords:  Biomarkers; Glioma; Immunotherapy; Isocitrate Dehydrogenase

Year:  2017        PMID： 29104858      PMCID： PMC5669623          DOI： 10.21037/tcr.2017.09.37

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  11 in total

1.  Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.

Authors:  Tiffany Doucette; Ganesh Rao; Arvind Rao; Li Shen; Kenneth Aldape; Jun Wei; Kristine Dziurzynski; Mark Gilbert; Amy B Heimberger
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

2.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  A vaccine targeting mutant IDH1 induces antitumour immunity.

Authors:  Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 6.  Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.

Authors:  Tiffany R Hodges; Bryan D Choi; Darell D Bigner; Hai Yan; John H Sampson
Journal:  J Neurosurg       Date:  2013-04-12       Impact factor: 5.115

7.  IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Authors:  Xiaoran Zhang; Aparana Rao; Paola Sette; Christopher Deibert; Alexander Pomerantz; Wi Jin Kim; Gary Kohanbash; Yigang Chang; Yongseok Park; Johnathan Engh; Jaehyuk Choi; Timothy Chan; Hideho Okada; Michael Lotze; Paola Grandi; Nduka Amankulor
Journal:  Neuro Oncol       Date:  2016-04-25       Impact factor: 12.300

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
View more
  8 in total

Review 1.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

Review 2.  Tumor-Agnostic Treatment for Cancer: When How is Better than Where.

Authors:  Daniele Lavacchi; Giandomenico Roviello; Alberto D'Angelo
Journal:  Clin Drug Investig       Date:  2020-06       Impact factor: 2.859

3.  An insight into the molecular genetics of a uveal melanoma patient cohort.

Authors:  Susan Kennedy; Michael Rice; Sinead Toomey; Noel Horgan; Bryan T Hennessey; Annemarie Larkin
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

4.  Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.

Authors:  Tyler J Alban; Alvaro G Alvarado; Mia D Sorensen; Defne Bayik; Josephine Volovetz; Emily Serbinowski; Erin E Mulkearns-Hubert; Maksim Sinyuk; James S Hale; Giovana R Onzi; Mary McGraw; Pengjing Huang; Matthew M Grabowski; Connor A Wathen; Manmeet S Ahluwalia; Tomas Radivoyevitch; Harley I Kornblum; Bjarne W Kristensen; Michael A Vogelbaum; Justin D Lathia
Journal:  JCI Insight       Date:  2018-11-02

Review 5.  Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.

Authors:  Artemiy S Silantyev; Luca Falzone; Massimo Libra; Olga I Gurina; Karina Sh Kardashova; Taxiarchis K Nikolouzakis; Alexander E Nosyrev; Christopher W Sutton; Panayiotis D. Mitsias; Aristides Tsatsakis
Journal:  Cells       Date:  2019-08-09       Impact factor: 6.600

6.  The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.

Authors:  Xing-Chen Ding; Liang-Liang Wang; Yu-Fang Zhu; Yan-Dong Li; Shu-Lun Nie; Jia Yang; Hua Liang; Ralph R Weichselbaum; Jin-Ming Yu; Man Hu
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

7.  Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.

Authors:  Jasneet Kaur Khalsa; Khalid Shah
Journal:  Cells       Date:  2021-02-25       Impact factor: 6.600

8.  gp96 Expression in Gliomas and Its Association with Tumor Malignancy and T Cell Infiltrating Level.

Authors:  Chunzhao Li; Yi Wang; Lang Long; Peng Zhang; Yang Zhang; Nan Ji
Journal:  J Oncol       Date:  2022-06-26       Impact factor: 4.501
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.